Management of pregnant women with antiphospholipid antibodies

References

• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Fox H, Backos M, et al. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002;17:1067–1071.
   PubMed Web of Science ®Google Scholar
• Di Simone N, Marana R, Castellani R, et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. Arthritis Rheum. 2010;62:1504–1512.
   PubMed Web of Science ®Google Scholar
• Shamonki JM, Salmon JE, Hyjek E, et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007;196:161–165.
   PubMedGoogle Scholar
• Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev. 2015;14:446–471.
   PubMed Web of Science ®Google Scholar
• Bose P, Black S, Kadyrov M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005;192:23–30.
   PubMed Web of Science ®Google Scholar
• Peaceman AM, Rehnberg KA. The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with lupus anticoagulant. Am J Obstet Gynecol. 1995;173:1391–1396.
   PubMed Web of Science ®Google Scholar
• Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. Am J Reprod Immunol. 1996;35:80–84.
   PubMed Web of Science ®Google Scholar
• de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795–813.
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174:1584–1589.
   PubMed Web of Science ®Google Scholar
• Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314:253–257.
   PubMed Web of Science ®Google Scholar
• Franklin RD, Kutteh WH. Antiphospholipid Antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod. 2002;17:2981–2985.
   PubMed Web of Science ®Google Scholar
• Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408–413.
   PubMed Web of Science ®Google Scholar
• Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol. 2009;36:279–287.
   PubMed Web of Science ®Google Scholar
• Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12:CR132–136.
   PubMed Web of Science ®Google Scholar
• Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipid syndrome. Arch Gynecol Obstet. 2012;285:641–647.
   PubMed Web of Science ®Google Scholar
• Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169:1411–1417.
   PubMed Web of Science ®Google Scholar
• Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183:1008–1012.
   PubMed Web of Science ®Google Scholar
• Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010;9:281–288.
   Web of Science ®Google Scholar
• Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and metaanalysis. Obstet Gynecol. 2010;115:1256–1262.
   PubMed Web of Science ®Google Scholar
• Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;2:CD002859.
   Google Scholar
• de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev. 2014;7:CD004734.
   PubMed Web of Science ®Google Scholar
• Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy - a systematic review of randomized therapeutic trials. Thromb Res. 2004;114:419–426.
   PubMed Web of Science ®Google Scholar
• Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of Antiphospholipid Antibody Syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26:729–734.
   PubMedGoogle Scholar
• Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005;83:684–690.
   PubMed Web of Science ®Google Scholar
• Fouda UM, Sayed AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet. 2011;112:211–215.
   PubMed Web of Science ®Google Scholar
• Wong LF, Porter TF, de Jesus GR. Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand? Lupus. 2014;23:1226–1228.
   PubMed Web of Science ®Google Scholar
• Clark CA, Spitzer KA, Laskin CA. Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring? J Rheumatol. 2015;42:155–157.
   PubMed Web of Science ®Google Scholar
• Bouvier S, Cochery-Nouvellon E, Lavigne-Lissalde G, et al. Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood. 2014;123:404–413.
   PubMed Web of Science ®Google Scholar
• Bao SH, Sheng SL, Liao H, et al. Use of D-dimer measurement to guide anticoagulant treatment in recurrent pregnancy loss associated with antiphospholipid syndrome. Am J Reprod Immunol. 2017;78:e12770.
   Web of Science ®Google Scholar
• de Jesus GR, Rodrigues G, de Jesus NR, et al. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep. 2014;16:403.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Hoxha A, et al. Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study. Thromb Haemost. 2018;118:639–646.
   PubMed Web of Science ®Google Scholar
• Stone S, Hunt BJ, Seed PT, et al. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and healthy pregnancy. Am J Obstet Gynecol. 2003;188:454–460.
   PubMed Web of Science ®Google Scholar
• Fischer-Betz R, Specker C, Brinks R, et al. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus. 2012;21:1183–1189.
   PubMed Web of Science ®Google Scholar
• Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19:58–64.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost. 2014;112:727–735.
   PubMed Web of Science ®Google Scholar
• Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome registry project group, catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–534.
   PubMed Web of Science ®Google Scholar
• Gomez-Puerta JA, Sanin-Blair J, Galarza-Maldonado C. Pregnancy and catastrophic antiphospholipid syndrome. Clin Rev Allerg Immunol. 2009;36:85–90.
   PubMed Web of Science ®Google Scholar
• Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517–523.
   PubMed Web of Science ®Google Scholar
• Hochfeld M, Druzin ML, Maia D, et al. Pregnancy complicated by primary antiphospholipid antibody syndrome. Obstet Gynecol. 1994;83:804–805.
   PubMed Web of Science ®Google Scholar
• Sinha J, Chowdhry I, Sedan S, et al. Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol. 2002;29:195–197.
   PubMed Web of Science ®Google Scholar
• Koenig M, Roy M, Baccot S, et al. Thrombotic microangiopathy with liver, gut and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol. 2005;2:166–168.
   Web of Science ®Google Scholar
• Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost. 2006;95:796–801.
   PubMed Web of Science ®Google Scholar
• Matsuki Y, Atsumi T, Yamaguchi K, et al. Clinical features and pregnancy outcome in antiphospholipid syndrome with history of severe pregnancy complications. Mod Rheumatol. 2015;25:215–218.
   PubMed Web of Science ®Google Scholar
• Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216:525.e1–525.e12.
   Web of Science ®Google Scholar
• Deguchi M, Yamada H, Sugiura-Ogasawara M, et al. Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: a multicenter study. J Reprod Immunol. 2017;122:21–27.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost. 2006;96:337–341.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Cavazzana A, et al. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res. 2009;123:482–487.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with antiphospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology. 2011;50:1684–1689.
   PubMed Web of Science ®Google Scholar
• Latino JO, Udry S, Aranda FM, et al. Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus. 2017;26:983–988.
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64:2311–2318.
   PubMed Web of Science ®Google Scholar
• Nodler J, Moolamalla SR, Ledger EM, et al. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth. 2009;9:11.
   PubMed Web of Science ®Google Scholar
• Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand. 2011;90:1428–1433.
   PubMed Web of Science ®Google Scholar
• Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33:2214–2221.
   PubMed Web of Science ®Google Scholar
• Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14:131–136.
   PubMed Web of Science ®Google Scholar
• Bowman ZS, Wünsche V, Porter TF, et al. Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss. J Reprod Immunol. 2015;107:59–63.
   PubMed Web of Science ®Google Scholar
• Danowski A, de Azevedo MN, de Souza Papi JA, et al. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol. 2009;36:1195–1199.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Sanna G, Murru V, et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015;54:134–138.
   PubMed Web of Science ®Google Scholar
• Parke A, Maier D, Wilson D, et al. Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med. 1989;110:495–496.
   PubMed Web of Science ®Google Scholar
• Wapner RJ, Cowchock FS, Shapiro SS. Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am J Obstet Gynecol. 1989;161:1271–1272.
   PubMed Web of Science ®Google Scholar
• Ron-El R, Vinder A, Golan A, et al. The use of intravenous gammaglobulin, heparin and aspirin in the maintenance of pregnancy of freeze thawed embryo in a patient with lupus-type anticoagulant. Eur J Obstet Gynecol Reprod Biol. 1993;52:131–133.
   PubMed Web of Science ®Google Scholar
• Kaaja R, Julkunen H, Ammälä P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand. 1993;72:63–66.
   PubMed Web of Science ®Google Scholar
• Arnout J, Spitz B, Wittevrongel C, et al. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost. 1994;71:741–747.
   PubMed Web of Science ®Google Scholar
• Somerset DA, Raine-Fenning N, Gordon C, et al. Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. Eur J Obstet Gynecol Reprod Biol. 1998;79:227–229.
   PubMed Web of Science ®Google Scholar
• Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group. Am J Obstet Gynecol. 2000;182:122–127.
   PubMed Web of Science ®Google Scholar
• Stojanovich L, Mikovic Z, Mandic V, et al. Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin. Isr Med Assoc J. 2007;9:555–556.
   PubMed Web of Science ®Google Scholar
• Mar N, Kosowicz R, Hook K. Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. J Thromb Thrombolysis. 2014;38:196–200.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Yamaguchi K, Motomura K, et al. Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome. Clin Exp Rheumatol. 2014;32:299–300.
   PubMed Web of Science ®Google Scholar
• Carreras LD, Perez GN, Vega HR, et al. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet. 1988;2:393–394.
   PubMed Web of Science ®Google Scholar
• Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol. 2001;45:174–179.
   PubMed Web of Science ®Google Scholar
• Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent foetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 2003;48:728–731.
   PubMed Web of Science ®Google Scholar
• Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet. 2009;104:223–225.
   PubMed Web of Science ®Google Scholar
• Laskin CA, Bombardier C, Hannah ME, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 1997;337:148–153.
   PubMed Web of Science ®Google Scholar
• Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011;117:6948–6951.
   PubMed Web of Science ®Google Scholar
• El-Haieg DO, Zanati MF, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007;99:236–241.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Marson P, Pengo V, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007;6:196–202.
   PubMed Web of Science ®Google Scholar
• Mayer-Pickel K, Horn S, Lang U, et al. Response to plasmapheresis measured by angiogenic factors in a woman with antiphospholipid syndrome in pregnancy. Case Rep Obstet Gynecol. 2015;2015:123408.
   PubMedGoogle Scholar
• Ruffatti A, Favaro M, Hoxha A, et al. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J Reprod Immunol. 2016;115:14–19.
   PubMed Web of Science ®Google Scholar
• Hauser AC, Hauser L, Pabinger-Fasching I, et al. The course of anticardiolipin antibody levels under immunoadsorption therapy. Am J Kidney Dis. 2005;46:446–454.
   PubMed Web of Science ®Google Scholar
• Marchetti T, Ruffatti A, Wuillemin C, et al. Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. J Thromb Haemost. 2014;12:910–920.
   PubMed Web of Science ®Google Scholar
• Rand JH, Wu XX, Quinn AS, et al. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19:460–469.
   PubMed Web of Science ®Google Scholar
• Kaplan YC, Ozsarfati J, Nickel C, et al. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81:835–848.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in antiphospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015;14:498–502.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214:273.e1–273.e8.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Alijotas-Reig J, Carrat F, et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev. 2017;16:730–734.
   PubMed Web of Science ®Google Scholar
• Gardiner C, Hills J, Machin SJ, et al. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus. 2013;22:18–25.
   PubMed Web of Science ®Google Scholar
• Cohn DM, Goddijn M, Middeldorp S, et al. Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost. 2010;8:2208–2213.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Loire-Berson P, Nicaise-Roland P, et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94:222–226.
   PubMed Web of Science ®Google Scholar
• Alijotas-Reig J, Ferrer-Oliveras R, EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012;21:766–768.
   PubMed Web of Science ®Google Scholar
• Del Ross T, Ruffatti A, Visentin MS, et al. Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol. 2013;40:425–429.
   PubMed Web of Science ®Google Scholar
• Arachchillage DRJ, Machin SJ, Mackie IJ, et al. Diagnosis and management ofnon-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113:13–19.
   PubMed Web of Science ®Google Scholar
• Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipidantibody testing. Semin Thromb Hemost. 2012;38:360–374.
   PubMed Web of Science ®Google Scholar
• de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–1773.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Pregnolato F, Andreoli L, et al. Beyond thrombosis: anti-β2GPIdomain 1 antibodies identify late pregnancy morbidity in anti-phospholipidsyndrome. J Autoimmun. 2018;90:76–83.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Mattia E, Tonello M, et al. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55:890–898.
   PubMed Web of Science ®Google Scholar
• Chauleur C, Galanaud JP, Alonso S, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost. 2010;8:699–706.
   PubMed Web of Science ®Google Scholar
• Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368:601–611.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticardiolipinantibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008;6:1693–1696.
   PubMed Web of Science ®Google Scholar
• Boffa MC, Lachassinne E, Boinot C, et al. Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost. 2009;102:25–28.
   PubMed Web of Science ®Google Scholar
• Kaaja R, Julkunen H, Viinikka L, et al. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstet Gynecol. 1993;81:327–331.
   PubMed Web of Science ®Google Scholar
• Julkunen H, Jouhikainen T, Kaaja R. Fetal outcome in lupus pregnancy: the prognostic significance of an untreated and treated lupus anticoagulant. J Rheumatol. 1994;21:970–971.
   PubMed Web of Science ®Google Scholar
• Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? organizing group of the antiphospholipid antibody treatment trial. Am J Obstet Gynecol. 1997;176:1099–1100.
   PubMed Web of Science ®Google Scholar
• Kahwa EK, Sargeant LA, McCaw-Binns A, et al. Anticardiolipin antibodies in Jamaican primiparae. J Obstet Gynaecol. 2006;26:122–126.
   PubMedGoogle Scholar
• Amengual O, Fujita D, Ota E, et al. Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: asystematic review. Lupus. 2015;24:1135–1142.
   PubMed Web of Science ®Google Scholar
• Li R, Daguzan M, Vandermijnsbrugge F, et al. Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis. Acta Clin Belg. 2014;69:433–438.
   PubMed Web of Science ®Google Scholar
• Ensom MHH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig. 2004;11:77–83.
   Google Scholar
• Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol. 1996;35:402–407.
   PubMed Web of Science ®Google Scholar
• Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181:1113–1117.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Gervasi MT, Favaro M, et al. Adjusted prophylactic doses of nadroparin plus low dose aspirin therapy in obstetric antiphospholipid syndrome. A prospective cohort management study. Clin Exp Rheumatol. 2011;29:551–554.
   PubMed Web of Science ®Google Scholar
• Erkan D, Merrill JT, Yazici Y, et al. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001;44:1466–1467.
   PubMed Web of Science ®Google Scholar
• Gris JC, Bouvier S, Molinari N, et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119:2624–2632.
   PubMed Web of Science ®Google Scholar
• Kim MY, Buyon JP, Guerra MM, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016;214:108.e1–108.e14.
   Web of Science ®Google Scholar
• É C-N, É M, Bouvier S, et al. Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. Haematologica. 2017;102:835–842.
   PubMed Web of Science ®Google Scholar
• Thurman JM, Kraus DM, Girardi G, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42:87–97.
   PubMed Web of Science ®Google Scholar
• De Carolis S, Botta A, Santucci S, et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allerg Immunol. 2010;38:116–124.
   PubMed Web of Science ®Google Scholar
• Reggia R, Ziglioli T, Andreoli L, et al. Primary antiphospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? Rheumatology. 2012;51:2186–2190.
   PubMed Web of Science ®Google Scholar
• Salmon JE, Heuser C, Triebwasser M, et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013.
   PubMed Web of Science ®Google Scholar
• Kim MY, Guerra MM, Kaplowitz E, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018;77:549–555.
   PubMed Web of Science ®Google Scholar
• Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol. 2018;9:1388.
   PubMed Web of Science ®Google Scholar
• Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report. Medicine (Baltimore). 2017;96:e6338.
   PubMed Web of Science ®Google Scholar
• Imseis HM, Zimmerman PD, Samuels P, et al. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Placenta. 1997;18:521–526.
   PubMed Web of Science ®Google Scholar
• Daher S, Fonseca F, Ribeiro OG, et al. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. Eur J Obstet Gynecol Reprod Biol. 1999;83:77–79.
   PubMed Web of Science ®Google Scholar
• Yu XW, Yan CF, Jin H, et al. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynaecol Obstet. 2005;88:44–48.
   PubMed Web of Science ®Google Scholar
• Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody induced pregnancy loss. J Immunol. 2005;174:485–490.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013;12:752–757.
   PubMed Web of Science ®Google Scholar
• Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. J Reprod Immunol. 2009;82:126–131.
   PubMed Web of Science ®Google Scholar
• Odiari EA, Mulla MJ, Sfakianaki AK, et al. Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Hum Reprod. 2012;27:2933–2940.
   PubMed Web of Science ®Google Scholar
• Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. J Reprod Immunol. 2017;124:15–20.
   PubMed Web of Science ®Google Scholar
• Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126:2933–2940.
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Pierangeli SS. Statins for the treatment of obstetric complications in antiphospholipid syndrome? J Reprod Immunol. 2010;84: 206. author reply 206–207.
   PubMed Web of Science ®Google Scholar
• Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. Br Med J. 2015;350:h1035.
   PubMed Web of Science ®Google Scholar